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Abstract
Tubulointerstitial kidney disease is an important cause of progressive renal failure whose aeti-
ology is incompletely understood. We analysed a large pedigree with maternally inherited
tubulointerstitial kidney disease and identified a homoplasmic substitution in the control region
of the mitochondrial genome (m.547A>T). While mutations in mtDNA coding sequence are a
well recognised cause of disease affecting multiple organs, mutations in the control region
have never been shown to cause disease. Strikingly, our patients did not have classical fea-
tures of mitochondrial disease. Patient fibroblasts showed reduced levels of mitochondrial
tRNAPhe, tRNALeu1 and reduced mitochondrial protein translation and respiration. Mitochon-
drial transfer demonstrated mitochondrial transmission of the defect and in vitro assays
showed reduced activity of the heavy strand promoter. We also identified further kindreds with
the same phenotype carrying a homoplasmic mutation in mitochondrial tRNAPhe (m.616T>C).
Thus mutations in mitochondrial DNA can cause maternally inherited renal disease, likely
mediated through reduced function of mitochondrial tRNAPhe.
Author summary
Mitochondria provide the cell’s energy through respiration, using glucose and oxygen to
produce ATP. Critical components for this process are encoded by maternally inherited
mitochondrial DNA. Mutations in mitochondrial DNA usually affect organs that use
energy intensively, notably the brain, eyes and muscles. Here we have discovered a variant
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in the promoter region of mitochondrial DNA in a large family with kidney disease and
normal function in other organs. We show that patient-derived mitochondria do not gen-
erate energy normally and have reduced promoter activity, leading to loss of mitochon-
drial gene expression. We also identify similar mutations that might provide a mechanism
for other cases of unexplained inherited kidney disease: two families with reduced cellular
respiration carry mutations affecting mitochondrial phenylalanine tRNA, normally
required for mitochondrial protein translation. Together, this study provides the first
example of a disease-causing mutation in the mitochondrial promoter, and also estab-
lishes that the kidney is particularly sensitive to different mutations in mitochondrial
DNA. As these can arise from a mutation in the promoter region of mitochondrial DNA
or in the tRNA itself, and both reduce the amount of mitochondrial phenylalanine tRNA,
this may provide a potential unifying mechanism for mitochondrially inherited kidney
disease.
Introduction
End stage renal disease (ESRD) is common, affecting over 660,000 individuals in the United
States in 2013 and is increasing in incidence[1]. Renal replacement therapy is life-saving for
these patients, but is associated with increased morbidity and mortality, and high cost. In a
proportion of cases (currently less than 1 in 10) a genetic cause is identified on the basis of a
clear family history and/or specific clinical features. Genetic factors are also presumed to make
a major contribution to the development of ESRD in patients without a clear-cut family history
of renal disease. Chronic tubulointerstitial nephritis is a significant, but poorly understood,
cause of progressive renal disease characterised by bland urinary sediment and histological evi-
dence of interstitial fibrosis and tubular atrophy. To date, mutations in UMOD, HNF1B, REN
and MUC1 have been shown to cause autosomal dominant tubulointerstitial kidney disease
(ADTKD)[2]. While these account for a substantial proportion of inherited tubulointerstitial
kidney disease, further mechanisms remain to be identified. Here we show that tubulointersti-
tial renal disease in a large family without other clinical features is caused by a substitution in
mitochondrial DNA. We found a single base substitution in the promoter sequence directing
heavy-strand transcription. Homoplasmic variants in the mtDNA control region are not tradi-
tionally considered to be pathogenic[3], but we show that this substitution alters transcription,
and reduced levels of mitochondrial tRNAPhe. This was accompanied by a defect in mitochon-
drial protein synthesis and a biochemical defect affecting multiple components of the respiratory
chain. Examination of additional families with unexplained tubulointerstitial kidney disease led
to the identification of two pedigrees with a substitution that directly alters the sequence and
concentration of the mitochondrial tRNAPhe., suggesting that defects in mitochondrial transcrip-
tion or translation can cause tubulointerstitial kidney disease.
Results
We investigated the inheritance of renal disease in a large multiply affected white English fam-
ily (Fig 1). Affected individuals developed progressive renal impairment from early adulthood,
with increased urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion (NAG to creatinine
ratio 73.9–183.8 μmol/h/g, normal < 28), without amino aciduria or renal Fanconi syndrome.
Renal biopsy tissue was available from four individuals, showing changes consistent with tubu-
lointerstitial kidney disease. Three individuals had received renal transplants with no evidence
of recurrent renal disease up to 26 years following transplantation. Across the pedigree,
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penetrance of significant renal disease by the fourth decade of life was 100%, although the age
of onset and speed of progression varied between individuals. Physical and intellectual devel-
opment has been normal. Neurological examination in a national referral centre for mitochon-
drial disease was normal, and imaging of the CNS did not reveal any distinctive features.
Multipoint linkage analysis failed to identify a shared chromosomal haplotype, using both
autosomal dominant and X-linked models of inheritance (S1 Fig). This was confirmed by con-
flicting homozygosity analysis of SNP data, which demonstrated no regions >1.0 cM that were
identical by descent in affected individuals, even allowing for a 20% phenocopy rate[4]. Whole
exome sequencing of two affected individuals failed to demonstrate any shared substitutions
or variants that were predicted to be deleterious in genes associated with ADTKD. No cytosine
insertions were identified in the MUC1 tandem repeat sequences by probe-extension assay.
Given the absence of paternal transmission in the pedigree, we sequenced the mitochon-
drial genome in urinary epithelial cells from affected patients. Mitochondria contain a 16.5 kb
Fig 1. Pedigree with maternally inherited renal disease and m.547A>T substitution. (A) Pedigree of family showing individuals affected
with chronic kidney disease (CKD, red symbols), and end-stage renal disease (ESRD, black symbols). One individual (yellow symbol) died
many years previously age 18 with a diagnosis of Batten’s disease based on electronmicroscopy of a skin biopsy showing characteristic
curvilinear bodies. We consider this to be unrelated to the renal disease (B) Renal biopsy showing evidence of focal tubular atrophy by light
microscopy (arrowed). (C) Renal biopsy showing mitochondria in a renal tubular epithelial cell which appear structurally normal on electron
microscopy. (D) Sanger sequencing of mtDNA from a control individual. (E) Sequence of an affected individual showing the homoplasmic
m.547A>T substitution.
doi:10.1371/journal.pgen.1006620.g001
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circular genome, encoding two mitochondria-specific ribosomal RNAs, 22 tRNAs and 13
transmembrane proteins which form part of the core of the multi-protein oxidative phosphor-
ylation (OxPhos) complexes I, III, IV and V [5]. Two promoters in the control region drive
transcription of the polycistronic light and heavy strand transcripts[6]. We detected a total of
41 benign polymorphisms, one novel insertion located in a small hypervariable region down-
stream of the light strand promoter (m.16038+1 insC) and a previously unreported substitu-
tion (m.547A>T) located within the heavy strand promoter (HSP) of the mtDNA control
region (S1 Table)[7]. We focussed our attention on the m.547A>T substitution, which was
present at homoplasmic levels in blood, saliva, urinary epithelial cells, and fibroblast samples
in all affected individuals [8], in 14 individual skeletal muscle fibres from one patient, and in
blood samples taken over 15 years apart. No mtDNA deletions or duplications were detected
on long-range PCR of DNA from blood, fibroblast or skeletal muscle.
A diagnostic skeletal muscle biopsy[9] indicated a subclinical reduction in the enzymatic
activity of complexes I and IV relative to citrate synthase (S3 Table). Cultured dermal fibroblasts
derived from four different patients showed a significantly reduced proliferation rate when galac-
tose was substituted for glucose in the growth medium, suggesting a defect in the mitochondrial
electron transfer chain (S2 Fig). Mitochondrial DNA copy number was increased by ~50% (S3
Fig), but citrate synthase activity was not significantly changed relative to control cells (S4 Table).
To further characterise the effects of the m.547A>T substitution, we directly measured the oxy-
gen consumption of cultured patient-derived dermal fibroblasts and of trans-mitochondrial
cybrids made by fusion of patient platelets (free of nuclear DNA but containing mitochondria)
and mitochondria-depleted 143B ρ0 cells[10]. Basal and maximal respiration rates were signifi-
cantly reduced in fibroblasts and cybrids, confirming a mitochondrially inherited respiratory
defect (Fig 2).
To investigate the mechanism of impaired mitochondrial respiration we examined the expres-
sion of mitochondrial transcripts in patient-derived and control cells (Fig 3). We observed a sig-
nificant reduction of heavy strand encoded RNR1 and MT-CO1 expression compared to light
strand ND6, consistent with reduced function of the HSP. We also performed quantitative North-
ern blot analysis to assess the expression of mitochondrial tRNA species in fibroblasts and cybrids
(Fig 3). This demonstrated a highly reproducible reduction in the expression of heavy strand
tRNAPhe and tRNALeu relative to light strand encoded tRNAGln. tRNAVal was also reduced but
this was less marked.
To gain insight into effects on mitochondrial protein homeostasis, we developed a quantita-
tive proteomic approach to analyse mitochondrially-enriched fractions of SILAC-labelled fibro-
blasts, which we term MitoSILAC. This showed a reduction of mtDNA-encoded components in
complex I, III, IV, and V in patients (Fig 4, annotated dots), but not in the exclusively nuclear-
encoded complex II components. In addition, the majority of nuclear-encoded components of
the respiratory chain complexes I, III and IV were also reduced, implying complex instability
secondary to a deficiency of mtDNA-encoded subunits. By contrast, nuclear-encoded subunits
of complex V (ATP synthase) were unchanged or up-regulated. The reduction of mitochond-
rially-encoded proteins was also pronounced in patient-derived cybrid lines as assessed by meta-
bolic labelling (S3 Fig).
To investigate if m.547A>T directly influences HSP activity, we employed a reconstituted
in vitro transcription system, containing purified mitochondrial transcription factors (Fig 5)
[11]. We used a shortened linear mtDNA template that contained both the LSP and HSP. The
relative expression of the two different length run-off transcripts allowed direct assessment of
HSP transcription relative to the LSP signal (Fig 5A). The m.547A>T substitution decreased
HSP transcription activity by 27 ± 7.2% compared to control, confirming a defect in HSP func-
tion (Fig 5B and 5C).
Mitochondrially inherited tubulointerstitial kidney disease
PLOS Genetics | DOI:10.1371/journal.pgen.1006620 March 7, 2017 4 / 17
Analysis of mitochondrial DNA of 62 other pedigrees with previously unexplained, but
potentially inherited, renal disease led to the identification of a different homoplasmic substi-
tution, in the anticodon stem of mt tRNA Phe (m.616T>C) in three families (S2 Table). Two
of these families (Pedigrees II and III, Fig 6A) originated from a study of 10 families with tubu-
lointerstitial kidney disease, which only identified a genetic cause in 7 of them[12]. We also
found the m.616T>C substitution in a family with tubulointerstitial renal disease which was
originally reported in 1982[13]. Further genealogic enquiries demonstrated that this family
is actually connected to Family 8 in Ref[12], and the combined kindred is shown in Pedigree
II (Fig 6A). Currently we have no genealogic evidence that pedigrees II and III are also con-
nected. However, both are from Australia, and their mtDNA sequence is identical, implying
a recent common maternal ancestor. Similar to the family with the m.547A>T HSP substitu-
tion, none of the affected individuals in these kindreds had clear evidence of extra-renal
disease.
To explore the functional consequences of the tRNAPhe substitution we studied oxygen
consumption of patient-derived cybrids which showed reduced basal and maximal respiration,
indicating that the patient-derived mitochondrial DNA was responsible for impaired
Fig 2. Mitochondrial function is impaired in m.547A>T fibroblasts and cybrids. Oxygen consumption rate (OCR) was measured to assess
mitochondrial function in fibroblasts (A, C) and cybrids (B, D), normalised for cell number. Representative comparison of fibroblasts (A) and cybrids (B)
from control individuals (red) with fibroblasts or cybrids from patients with the m.547A>T substitution (blue) showing a substantial change in respiratory
profile. There was a significant decrease in baseline oxygen consumption, and in maximal oxygen consumption following addition of FCCP in both
fibroblasts (C) and cybrids (D). Asterisks *p < 0.05, **p < 0.005, and ***p < 0.001 for control versus patient groups, represented as the mean ± SD of
separate experiments performed in triplicate with four patient and four control cell lines.
doi:10.1371/journal.pgen.1006620.g002
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respiration (Fig 6B). Analysis of patient fibroblasts revealed a reduction of the level of tRNAPhe
to an extent similar to that which we observed in patients with the HSP substitution (Fig 6C).
Discussion
We consider that the m.547A>T substitution in the HSP of mtDNA is a pathogenic substitu-
tion for the following reasons. First, it segregated with renal disease in 18 members of a mater-
nal lineage and was not seen in 29,867 population controls[7]. Second, it was associated with
decreased mitochondrial respiration in skin fibroblasts from multiple affected individuals and
in cybrid cell lines. Third, it was associated with deficiency of multiple respiratory chain com-
plexes in a skeletal muscle biopsy from an affected individual and four different fibroblast cell
lines, supporting an abnormality of intra-mitochondrial protein synthesis. Fourth, it was asso-
ciated with reduced MT-CO1 and mitochondrial tRNA transcripts, consistent with reduced
function of the mtDNA HSP. Fifth, it resulted in decreased HSP transcription in vitro. Finally,
Fig 3. Reduced expression of mitochondrial heavy strand transcripts in m.547A>T patient-derived cells. (A, C)
RNA from patient- and control-derived cells (n = 4 each) was analysed for expression of a panel of mitochondrial tRNAs by
quantitative Northern blot. The graphs show mean expression of heavy strand tRNAs relative to light strand tRNA Gln(Q).
Values are expressed relative to the mean for the control cell lines in each case. Error bars indicate the standard deviation.
Heavy strand tRNAPhe and tRNALeu expression is reduced relative to light strand tRNA Gln in m.547A>T fibroblasts (A,
p<0.001) and cybrids (C, p<0.001 for tRNA Phe(F), Val (V) and Leu (L)). Experiments were repeated three times with
equivalent results. Labelling for 5S rRNA was used to confirm equal loading. Heavy chain transcripts RNR1 (B) and CO1 (D)
were measured by quantitative RT-PCR and were reduced in m.547A>T cybrids relative to the light strand transcript ND6.
Each point represents the mean of several independent cybrid cell lines derived from a single donor.
doi:10.1371/journal.pgen.1006620.g003
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a related mtDNA substitution was identified in other pedigrees with a similar clinical and bio-
chemical phenotype. To the best of our knowledge m.547A>T is the first substitution in the
mitochondrial transcriptional control region that has been shown to cause disease. Interest-
ingly, a m.547A>G substitution has been recorded previously without any reported disease
association. It is therefore likely that this alternative substitution does not have a functional
effect, consistent with the structural impact of such a purine to purine transition being less
severe than a purine to pyrimidine transversion [14].
The m.616T>C substitution alters an evolutionarily conserved base, the only pseudouri-
dine in mitochondrial tRNAPhe, and will disrupt the last base pairing before the anticodon
loop. Reinforcing the pathogenic nature of this substitution, Zsurka et al. described an individ-
ual with m.616T>C at near-homoplasmic levels who had intractable epilepsy and develop-
mental delay[15]. Interestingly, she had chronic renal insufficiency when she died at the age of
17, and a maternal relative had died from kidney failure and had epilepsy starting in child-
hood. Two of the m.616T>C individuals in Pedigree II who are now deceased had epileptic
Fig 4. m.547A>T fibroblasts display a marked reduction in complex I, III and IV protein expression. Four individual pairs of
fibroblasts from different patients and controls were SILAC labelled and the mitochondrial fraction was analysed by LC-MS/MS. The ratio of
protein levels in patient versus control cells is displayed on a log2 scale. Respiratory chain proteins which were quantified in at least two pairs
are shown. All identified mitochondrial-encoded proteins are annotated (ND1-5: NADH dehydrogenase subunit 1–5, CYT-B: cytochrome b,
COII: cytochrome c oxidase II, ATP6: ATP synthase 6. See S4 Fig for complete annotation). The size of each dot indicates the significance
(adjusted p value) of the difference in abundance of the protein in the patient and control samples. Location below the line of equivalence (0.0)
indicates lower abundance in the patient samples compared to controls.
doi:10.1371/journal.pgen.1006620.g004
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seizures which are described in Burke et al.[13]. Although we have not detected neurological
abnormalities in living individuals from this family or in Pedigree III, taken together with the
report of Zsurka et al, this suggests that m.616T>C may be associated with a reduced threshold
for epileptic seizures. Previous reports of substitutions in mitochondrial tRNAPhe provide
some further support for the notion that renal function is sensitive to perturbing this mito-
chondrial tRNA. Tzen et al. described two siblings with m.608A>G substitutions (the partner
nucleotide of 616T in the anticodon stem), neurological features and a urinary concentrating
defect[16]. D’Aco et al. reported a child with a heteroplasmic m.586G>A substitution, persis-
tent lactic acidosis, failure to thrive and progressive renal failure[17]. Mitochondrial tRNAPhe
is one of two tRNAs that can form a structural component of the mitoribosome[18] which
could exacerbate the translational defect. Although minor abnormalities in proximal tubular
function are frequent in patients with other mitochondrial mutations, clinically overt renal dis-
ease is not usually observed[19]. Taken together with our study, these observations suggest
that renal function is particularly susceptible to specific alterations in tRNAPhe.
In all the individuals described in this report it is striking that despite the mitochondrial
defect being homoplasmic and present in all tissues clinical disease was restricted to the kid-
ney, although we acknowledge that other organs may be affected at a subclinical level. This sit-
uation is similar to the organ specific effect of mutations in mt tRNAIle, which primarily cause
hypertrophic cardiomyopathy [20][21] and of mutations in NADH dehydrogenase causing
Fig 5. m.547A>T impairs mitochondrial heavy strand promoter activity. (A) In vitro transcription with purified mitochondrial
transcription factors and a dual promoter construct containing the heavy (HSP) and light strand promoter (LSP) was used to
assess the effect of the m.547A>T substitution. The linear template results in run off (RO) transcripts of 190 nucleotides (nt) from
the HSP and 90 nt from the LSP. (B) Metabolically labelled transcripts from wild type (wt) and m.547A>T variant promoter
(A547T) were analysed by autoradiography. (C) Analysis of relative band intensities of (B) shows a significant reduction of HSP
activity in the presence of the m.547A>T substitution (p = 0.0014). The experiment was performed three times yielding the same
result.
doi:10.1371/journal.pgen.1006620.g005
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Leber’s hereditary optic neuropathy [22]. Taken together, the contrasting effects of these muta-
tions should offer a powerful route to understanding how mitochondrial defects cause disease
in different tissues.
From a clinical perspective, we propose the term Mitochondrially Inherited Tubulointersti-
tial Kidney Disease (MITKD) to complement the recently defined entity, Autosomal Domi-
nant Tubulointerstitial Kidney Disease (ADTKD)[2]. MITKD may account for a significant
proportion of unexplained familial tubulointerstitial kidney disease and we recommend that
Fig 6. mt.616T>C cybrids have a defect in respiration. (A) Two pedigrees showing potential maternal inheritance of renal disease. Individ-
uals with kidney disease are represented by filled shapes as in Fig 1. Family 8 from ref 13 forms part of pedigree II, and is indicated by the dotted
box. Pedigree III is Family 6 from ref 13. Individuals from whom DNA was sequenced in the current study are marked with asterisks. All affected
individuals who were sequenced were found to have homoplasmic levels of the m.616T>C substitution. The mitochondrial haplotype is T1a1. (B)
Measurement of oxygen consumption in patient-derived and control cybrids showing a reduction in basal (before addition of oligomycin) and
maximal respiration (after addition of FCCP) in patient-derived cybrids. (C) Expression levels of tRNAs quantified by Northern blot of three control
and patient-derived cybrids show reduced mitochondrial tRNAPhe levels relative to the light strand encoded tRNAGln in mt.616T>C cells.
(p = 0.006) The tRNA levels for valine and leucine were unaffected. (D) Conservation of mt tRNA Phe within vertebrates. The anticodon (GAA) is
highlighted in bold, the nucleotides forming the last pair of the anticodon stem are underlined. Sequences were aligned with clustal omega and
manually adjusted. The stem (s) and loop (l) secondary structure of the tRNA Phe of humans is indicated at the bottom.
doi:10.1371/journal.pgen.1006620.g006
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kindreds with compatible patterns of transmission should be offered analysis of mitochondrial
DNA as a route to establishing a diagnosis and appropriate genetic counselling.
Materials and methods
Genetic analysis
DNA was extracted from peripheral-blood leukocytes, urinary epithelial cells, and saliva. 1 μg
of genomic DNA at 75 ng/μl was used for SNP genotyping. Individuals were genotyped using
300,000 single nucleotide polymorphism (SNP) markers with an average separation of 6.1 kb
on the Illumina CytoSNP 12 chip (Illumina, Cambridge, UK). Genotyping was performed at
the automated, high-throughput system available at UCL Genomics. Linkage analysis was per-
formed on pedigrees using the easyLINKAGE Plus v5.05 graphical user interface for two-/
multi-point linkage analysis [23], with analysis by GeneHunter[24] and SimWalk [25]. Pedi-
grees were confirmed using HaploPainter V.1.043[26] and PedCheck[27]. For calculation of
parametric LOD scores a ‘rare dominant’ model was utilised, with disease allele frequency set
to 10–4 and disease penetrance vector set to 1.0. Conflicting homozygosity was assessed in
this genotype data, using a program written by Dr Daniel Gale and Dr Adam Levine at UCL.
mtDNA was analysed by Sanger sequencing. Long-range PCR was performed using published
primers[28]. Homoplasmy analysis was performed using labelled amplicons from the D4
primer pair[28] and tetra-primer amplification refractory mutation system PCR designed to
detect the m.547A>T substitution.
Muscle biopsy analysis
A quadriceps muscle biopsy was taken from one affected individual, snap frozen, and analysed
using enzyme histochemistry and respiratory chain complex analysis as described[29]. Indi-
vidual skeletal muscle fibres were isolated by laser capture for quantitative pyrosequencing to
determine whether there was any intracellular heteroplasmy[30].
Generation of cell lines
Fibroblasts from four different patients and four healthy volunteers were obtained by skin
biopsy and cultured in Dulbecco’s Modified Eagle’s medium, supplemented with pyruvate and
uridine. Cybrids were created by fusion of 143B ρ0 cells and enucleated patient fibroblasts or
platelets as described[10]. Cell lines were confirmed to contain the promoter variant by
sequencing. All lines tested negative for mycoplasma. All donors consented to research use of
their skin-derived primary cells. Volunteers were enrolled at UCL London, study reference 06/
Q0406/151.
Respiration assays
Oxygen consumption rate was determined with a Seahorse XF24 Analyser (Seahorse Bio-
science, MA) and normalised for cell number. Respiratory profiles were generated by
serial treatment with optimised concentrations of oligomycin (0.5–5 μg/ml), p-[trifluoro-
methoxy]-phenyl-hydrazone (FCCP) (1–7.5 μg/ml), and antimycin[31] (2–4 μg/ml), with
fibroblasts receiving the higher and cybrids the lower concentration. Cell number normal-
isation was done by sulforhodamine B staining of TCA fixed cells in the seahorse plate as
described[32].
Mitochondrially inherited tubulointerstitial kidney disease
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Investigation of mitochondrial gene expression
Quantitative reverse-transcriptase-polymerase chain reaction (qRT-PCR) TaqMan assays
(Applied Biosystems, CA) were used to measure the expression of mitochondrially encoded
messenger RNA. The following primers were used:
β-Actin forward CCCAGAGCAAGAGAGG, reverse GTCCAGACGCAGGATG;
E-cadherin forward GACAACAAGCCCGAATT, reverse GGAAACTCTCTCGGTCCA;
B2M (RNA) forward GTGCTCGCGCTACTCTCTCT, reverse TCAATGTCGGATGGATGA
AA;
MT-CO1 forward ACGTTGTAGCCCACTTCCAC, reverse CATCGGGGTAGTCCGAGT
AA;
RNR1 forward CTAGCCACACCCCCACGGGA, reverse CGCGGTGGCTGGCACGAAAT;
ND6 forward AGGTAGGATTGGTGCTGTGG, reverse CCAATAGGATCCTCCCGAAT.
High resolution Northern blotting
RNA was prepared in Trizol (Invitrogen) according to the manufacturers recommendations,
resuspended in formamide and 1 μg separated on a 15% polyacrylamide/TBE gel. RNA was
then transferred by wet blotting onto Immobilon NY+ nitrocellulose membranes (Millipore,
Watford, UK) and crosslinked in a Stratalinker at 120 mJoules. The crosslinked membranes
were transferred to hybridisation tubes and pre-hybridised for an hour at 42˚C in hybridisa-
tion solution (50% formamide, 10% dextran sulfate, 1% SDS, 5x Denhardt’s solution in 5x
SSPE buffer). Random-labelled probes were generated by incubating 100 ng PCR amplified
tRNA and 5S rRNA templates with 1.85 MBq α-32P dCTP (Perkin Elmer, Seer Green, UK),
random decanucleotides and Klenow polymerase exo- fragment (Thermo Scientific DecaLabel
DNA Labelling Kit, Waltham, MA). The following primers were used to generate the PCR
products:
Phe: 71 nt, Fwd: GTTTATGTAGCTTACCTCCTCA, Rev: GATGTGAGCCCGTCTAAACA
Gln: 69 nt, Rev: AGGACTATGAGAATCGAACCC, Fwd: GATGGGGTGTGATAGGTGGC
Leu 1 (UUR): 75 nt, Fwd: TTAAGATGGCAGAGCCCG, Rev: TTGTTAAGAAGAGGAATTG
AACC
Val: 69 nt, Fwd: AGCTTAACACAAAGCACCCA, Rev: TCAGAGCGGTCAAGTTAAG
5S rRNA (RNA5S1): 121 nt, Fwd: GTCTACGGCCATACCACCCTG, Rev: AAAGCCTACAG
CACCCGGTAT
Probes were purified on NICK columns (GE healthcare, Sale, UK) and a specific activity of
2x10^6 cpm was added to the membranes in hybridisation solution and incubated over night
at 42˚ C. Up to 3 probes were used together (two tRNAs and 5S rRNA). The membranes were
rinsed three times with 2x SSPE at room temperature and once with 2X SSPE/2%SDS for 15
minutes at 65˚. Bound probe was quantified by phosphorimaging.
Mitochondrial DNA promoter assay
The transcription reactions were performed as described previously (Posse et al. 2014) with
100 mM NaCl, 400 nM TFAM, 20 nM POLRMT, 60 nM TFB2M and 4 nM template. The
templates used were obtained by restriction cleavage (MscI and HindIII) of pUC18 plasmids
Mitochondrially inherited tubulointerstitial kidney disease
PLOS Genetics | DOI:10.1371/journal.pgen.1006620 March 7, 2017 11 / 17
containing a mitochondrial DNA insert (human mtDNA 1–741, 547A or 547A>T) generating
run-off products of 90 and 190 nucleotides from the light and heavy strand promoters. The α-
32P-UTP labelled transcription products were separated on a 4% Urea PAGE and exposed on
a phosphorimager plate. HSP transcript levels were quantified and normalized to LSP tran-
scription from the same reaction.
MitoSILAC
Patient derived fibroblasts were incubated with normal (light) amino acids while control fibro-
blasts of the same low passage number were incubated with 13C6 Arginine and 13C8 Lysine
(heavy) for at least 5 passages. Pairs of patient and control fibroblasts were mixed at 1x10^7
cells each and lysed by dounce homogenisation. Mitochondria were enriched as previously
described by differential centrifugation followed by further enrichment on a Percoll gradient
[33].
50 μg of enriched mitochondria were resolved approximately 6 cm into a pre-cast 4–12%
Bis-Tris polyacrylamide gel (Novex, Thermo Fisher Scientific, East Grinstead, UK). The lane
was excised and cut in 8 approximately equal chunks and the proteins reduced, alkylated and
digested in-gel. The resulting tryptic peptides were analysed by LC-MSMS using a Q Exactive
coupled to an RSLCnano3000 (Thermo Fisher Scientific). Raw files were processed using Max-
Quant 1.5.2.8 using Andromeda to search a human Uniprot database (downloaded 03/12/14).
Acetyl (protein N-terminus), oxidation (M) and deamidation (N/Q) were set as variable modi-
fications and carbamidomethyl (C) as a fixed modification. SILAC data was loaded in R to
process it with the Microarray-oriented limma package to call for differential expression[34],
relying on the original normalisation processes produced by MaxQuant as reported previously
[35, 36]. The proteomics data was deposited to the ProteomeXchange Consortium via the PRIDE
[37] partner repository with the dataset identifier PXD004809. A linear model was fitted with
limma for the log-2 normalised expression ratios; moderated t-statistics, moderated F-statistics,
log-odds and associated p-values for differential expression were produced with the same pack-
age. P-values were corrected for multiple hypothesis testing. Proteins were matched to the differ-
ent mitochondrial respiratory complexes based on the gene family annotation available at HGNC
[38] and plotted using ggplot2 [39]. Low variance of the data between individual donors is indi-
cated by the low incidence of standard deviation greater than 20% as shown in S3 Fig.
Mitochondrial translation assay
Quantitation of mitochondrial protein translation was done as described by Chomyn[40].
Cells were grown to 80% confluence in 6 well dishes, starved for 20 min in medium without
methionine and cysteine, cytosolic translation was blocked with emetine (100 ug/ml) for 30
min before adding 6.8 MBq radiolabelled 35S methionine/cysteine (EasyTag Express35S, Per-
kin Elmer, Seer Green, UK) for 30 min. Washed cells were harvested and separated on TGX
Stain-Free precast gels (Bio-Rad, Marnes La Coquette, France), equal loading was confirmed
by UV imaging (ChemiDoc, Bio-Rad) prior drying and exposure to phosphorimager screens
Statistical analysis
Unless otherwise stated, Student’s t-test was used to assign significance, assuming normal dis-
tribution of variance (two-tailed, non-paired). Mean and standard deviation are indicated
where appropriate.
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Accession numbers
The traces of the whole mitochondrial sequencing for the m.547A>T variant can be found in
the NCBI trace archive, accession number TI 2344039844–2344039995. The mass spectrome-
try proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE
[37] partner repository with the dataset identifier PXD004809.
Supporting information
S1 Fig. Linkage analysis demonstrates lack of autosomal inheritance. (A) Linkage analysis
was performed on all affected individuals (n = 16) with elevated creatinine, using SNP data
from the Illumina CytoSNP 12 chip (Illumina, USA). Rare dominant and X-linked models
were used and the maximal LOD score (2.64) was considered non-significant given the size of
the pedigree (16 individuals which would require a LOD score of 5.1 or above).(B) Linkage
analysis on only the ESRD patients (n = 9) also yielded no significant hits (expected LOD score
of 3 or above).
(DOCX)
S2 Fig. Reduced growth of patient fibroblasts in galactose. Fibroblast lines from four differ-
ent patients and four healthy controls were cultured with either glucose (filled symbols) or
galactose (open symbols) as a carbon source and confluency was measured with an Incucyte
HD live cell imaging system. Patient-derived cells in galactose needed a mean value of 40
hours longer to reach 50% confluency compared to glucose. Control cells in galactose reached
50% confluency significantly faster, mean value of 19 hours later than cells supplied with glu-
cose (p = 0.019)
(DOCX)
S3 Fig. Increased mtDNA copy number in patient fibroblasts. Mitochondrial copy number
was assessed by quantitative RT-PCR for the mitochondrial gene ND1 and the nuclear gene
B2M and normalized to the mean ratio of healthy controls. As a group, patient-derived fibro-
blasts showed a significant increase in copy number relative to control fibroblasts (of different
haplotypes).
(DOCX)
S4 Fig. m.547A>T cybrids display reduced protein translation. Mitochondrial protein
translation was analysed by blocking cytosolic translation with emetine in the presence of 35S
methionine and cysteine. (A) A clear reduction of mitochondrial protein synthesis was observed
in the patient-derived cybrids with the m.547A>T substitution. The characteristic bands of
mitochondrial encoded proteins are annotated (ND1-6: NADH dehydrogenase subunit 1–6,
CO I-III: mitochondrially encoded cytochrome c oxidase I-III, ATP6: mitochondrially encoded
ATP synthase 6). (B) Total protein concentration of the radiolabelled samples was determined
using TGX stain free gels (Bio Rad). (C)The scatter plot shows the mean, normalised mitochon-
drial protein production of patient and control cybrids with error bars indicating the standard
deviation (p<0.01).
(DOCX)
S5 Fig. Fully annotated mitoSILAC data. Individual subunits of the respiratory complexes
identified in at least two of the four mitoSILAC experiments are listed. The binary logarithm of
the fold change is shown (LogFC). Error bars are shown where the standard deviation exceeded
20% of the mean. The adjusted p value indicating significant changes is indicated by a blue to
red colour scale. Uniprot gene names are given.
(DOCX)
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S1 Table. mtDNA variants in pedigree I. Base indicates the position relative to the revised
Cambridge reference sequence of human mitochondrial DNA; the GB frequency data is
derived from 29,867 GenBank sequences with size greater than 15.4kbp and published on the
MITOMAP database. A value of 1 indicates 100% prevalence.[7] The mitochondrial haplotype
is N1a1a1a, based on 22 indicative mtDNA variants.
(DOCX)
S2 Table. mtDNA variants in pedigrees II and III. Base indicates the position relative to the
revised Cambridge reference sequence of human mitochondrial DNA; the GB frequency data
is derived from 29,867 GenBank sequences with size greater than 15.4kbp and published on
the MITOMAP database. A value of 1 indicates 100% prevalence [7].
(DOCX)
S3 Table. Muscle biopsy shows reduced complex I and IV activity. Biochemical analysis of
skeletal muscle homogenate from a patient carrying the m.547A>T mutation showed that the
activities of complexes I and IV are both outside the control range, while complexes II and III
activities are normal. All enzyme activities are normalised for citrate synthase activity. Values
outside the normal range are shown in bold.
(DOCX)
S4 Table. Citrate synthase activity of patient and control fibroblasts. Citrate synthase activ-
ity in total cell lysates was assessed by measuring the conversion of oxaloacetate and acetyl
CoA to citrate and CoA-SH, which then reacts with dithio-nitrobenzoic acid (DTNB) to yield
thio-nitrobenzoate which absorbs at 412 nm[41]. We analysed four different patient and con-
trol cell lines (3 technical repeats per experiment and the assay was repeated twice). The ratio
of citrate synthase activity in patient and control fibroblast lines did not show a significant dif-
ference in any of the assays.
(DOCX)
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